R&D spending in the pharmaceutical industry through 2015 was valued at around $58bn as organisations vied to gain a competitive advantage by bringing new drugs to market as quickly as possible. Materials science is now helping pharmaceutical companies to standardize and control areas such as drug form and manufacture to deliver new products more quickly and with greater quality. The pharma industry is increasingly embracing the principles of Quality by Design (QbD) to improve efficiency and ensure good quality and reduced variability throughout the drug production process.
Proportional valve technology in process automation offers a great a deal of flexibility and produces high-quality control results. A complete system supplied by Festo and installed in Boehringer Ingelheim's new technical centre demonstrates the performance that modern pneumatics can deliver. The project was developed in close communication between the Festo team and automation experts from the pharmaceutical company, allowing it to move forward quickly.
Today’s biotech and pharmaceutical production facilities must drive faster times to market and greater profitability for new products by boosting production yields and accelerating commercialization and scaling of capacity.
AstraZeneca is a global, science-led biopharmaceutical business. They are one of a handful of companies to span the entire life cycle of a medicine – from research and development to manufacturing and supply – as well as the global commercialization of primary care and specialty care medicines. Operating in more than 100 countries, AstraZeneca employs around 57,500 people worldwide. The company has manufacturing operations in 17 countries, and their innovative medicines are used by millions of patients worldwide.
As the demand for complex, portable medical devices continues to grow, reducing risk and increasing efficiency during the development of these products should be paramount.